

Special Issue

Cannabidiol: Advances in Therapeutic Applications and Future Perspectives

Message from the Guest Editors

Cannabidiol (CBD) is one of the main natural cannabinoids found in *Cannabis sativa*. Due to the lack of psychotropic effects associated with Δ^9 THC and its good safety profile, CBD is the most interesting cannabinoid from a pharmacological point of view. Beneficial therapeutic effects have been reported in patients with inflammatory, neurodegenerative, and autoimmune diseases as well as in those with epilepsy and cancer. This Special Issue aims to provide readers with the most recent advances in this field. Authors are invited to submit relevant original articles, reviews or short communications for inclusion. Keywords: cannabis; cannabidiol; experimental medicine; pharmacology; biochemistry; natural products; inflammatory diseases; autoimmune diseases; cancer; epilepsy; neurodegenerative diseases

Guest Editors

Dr. Maurizio Bifulco

Department of Molecular Medicine and Medical Biotechnology,
University of Naples 'Federico II', Via S. Pansini 5, Naples, Italy

Dr. Simona Pisanti

Department of Medicine, Surgery and Dentistry 'Scuola Medica
Salernitana', University of Salerno, Via S. Allende 84081, Baronissi, SA,
Italy

Deadline for manuscript submissions

closed (31 March 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/48943

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)